The technology was approved by FDA in June and unveiled at the Scientific Sessions of the American Diabetes Association.
Medtronic today announced that its MiniMed Connect technology, which displays diabetes data from an insulin pump and continuous glucose monitor (CGM) on a smartphone, is now shipping in the United States.
The product received FDA approval in June and was displayed at the 75th Scientific Sessions of the American Diabetes Association in Boston. MiniMed Connect is part of a wave of technology products for persons with diabetes that marry traditional medical devices with smartphone or other consumer technology, to make glucose monitoring more discreet and convenient.
Among other features, MiniMed Connect allows persons other than the patient, such as parents or spouses, to remotely monitor diabetes information through management software known as CareLink Personal. (The Dexcom G4 Platinum with Share technology offers similar capabilities.)
MiniMed Connect is compatible with Medtronic’s MiniMed 530G and MiniMed Revel CGM systems. Right now, the related smartphone app works with iOS devices, and Medtronic is working with Samsung to develop an Android-compatible app, according to a statement from the company.
Patients can allow healthcare providers to access diabetes information through CareLink reports, which eliminates the need for patients to record blood sugars or other information between visits. “Effective management of diabetes requires an engaged team of participants, and MiniMed Connect serves to inform and involve people with diabetes, their loved ones and their healthcare professionals,” Annette Bruls, Medtronic president of Diabetes Services and Solutions, said in a statement.
Rapid advances in CGM technology come as pressure grows for Medicare to cover it, as most commercial insurers do. There is concern among patient advocacy groups that Medicare’s failure to cover CGM thus far, enough though it has become the standard of care in type 1 diabetes, could mean the nation’s largest payer would not cover artificial pancreas technology, which is on the horizon. Already, technologies that have been labeled “artificial pancreas” are announcing results of at-home trials.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More